射干麻黄汤加减联合信必可治疗哮喘-慢性阻塞性肺疾病重叠综合征急性发作期临床研究

发布时间：2018-03-11 22:03

本文选题：哮喘-慢性阻塞性肺疾病重叠综合征　切入点：射干麻黄汤　出处：《南京中医药大学学报》2017年05期 　论文类型：期刊论文

【摘要】：目的观察射干麻黄汤联合信必可治疗哮喘-慢性阻塞性肺疾病重叠综合征(ACOS)急性发作期的临床疗效。方法将42例痰湿阻肺证ACOS患者按随机数字法分为试验组(22例)和对照组(20例),在吸氧、止咳化痰、扩张支气管、抗感染等常规西药对症治疗基础上,对照组予信必可吸入,试验组予射干麻黄汤联合信必可治疗,疗程为4周,观察2组治疗效果。结果临床疗效上,试验组和对照组患者的总有效率为96.00%和65.00%,组间比较,P0.05;第1秒用力呼气量占预计值百分比(FEV1%)、第1秒用力呼气量占用力肺活量百分比(FEV1/FVC)较对照组明显升高,P0.05,CO弥散量(DLCO)试验组较对照组略升高,P0.05;哮喘控制测试评分(CAT)为(16±2)较对照组(20±2)显著降低,慢性阻塞性肺疾病评分(ACT)为(24±3)较对照组(16±2)显著提升,P0.05~0.01;2组皆无严重不良反应。结论射干麻黄汤联合信必可治疗ACOS急性发作期疗效满意,无严重不良反应,值得推广。
[Abstract]:Objective to observe the clinical effect of Sheganmahuang decoction combined with Xinpike in the treatment of acute attack of asthmatic chronic obstructive pulmonary disease overlap syndrome (ACOS). Methods 42 cases of ACOS with phlegm dampness blocking lung syndrome were divided into two groups according to random number method. ) and control group (n = 20). On the basis of traditional western medicine, such as relieving cough and resolving phlegm, dilating bronchi and anti-infection, the control group was inhalable, while the experimental group was treated with Sheganmahuang decoction combined with Xinji for 4 weeks. The therapeutic effect of the two groups was observed. The total effective rates of patients in the trial group and the control group were 96.00% and 65.00, respectively (P 0.05; forced expiratory volume as a percentage of the predicted value at 1 seconds; FEV1 / FVC at 1 seconds; FEV1 / FVC-1) significantly higher than that in the control group (P 0.05CO). Compared with the control group, the control test score of CAT was 16 卤2, which was significantly lower in the trial group than that in the control group (20 卤2). The score of chronic obstructive pulmonary disease (ACOS) was 24 卤3), which was significantly higher than that of control group (16 卤2). There were no serious adverse reactions in both groups. Conclusion Sheganmahuang decoction combined with Xinbiyou can be used to treat ACOS with satisfactory curative effect and no serious adverse reaction, which is worth popularizing.
【作者单位】：南京中医药大学基础医学院;泰州市中医院呼吸科;
【分类号】：R562.25;R563.9

【相似文献】